Pfizer Bets Billions on Obesity Market Entry with Metsera Acquisition
Published on 09/26/2025 at 05:27 | Redaktion boerse-global.de
In a bold strategic pivot, pharmaceutical giant Pfizer is making a monumental move into the obesity drug market. The company has agreed to acquire Metsera, a specialist in weight-loss medications, for a deal valued at up to $7.3 billion. This high-stakes acquisition comes after Pfizer’s internal drug candidate, danuglipron, failed in clinical trials, prompting a shift in strategy from in-house development to a targeted purchase.
Faced with the collapse of its own obesity treatment program, Pfizer is opting for a faster route to market. The acquisition of Metsera provides immediate access to a pipeline of advanced drug candidates that Pfizer claims could offer superior efficacy and tolerability compared to existing therapies. This move signals a significant departure from relying solely... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
